Dispatches From The Cancer Front
The results of some 2,000 cancer research studies were presented at the American Society of Clinical Oncology's annual meeting in Los Angeles on May 16-19. This year's meeting generated unusual excitement, as many years of basic research appear finally to be paying off with new methods of cancer treatment and prevention. More than 19,000 scientists and doctors crowded into meeting rooms and auditoriums to get their first glimpse of the latest ammunition in the war against cancer. Genentech Inc.'s new breast cancer drug, Herceptin, generated much of the buzz, but as BUSINESS WEEK Associate Editor Catherine Arnst reports, other significant findings were announced:
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- A L'Oreal Heiress Is Now the World's Richest Woman
- Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
- How Electric Cars Can Create the Biggest Disruption Since the iPhone
- Uber Losing Battle in London After Regulator Revokes License
- A Storm's Never Destroyed a Grid Like Maria Ruined Puerto Rico's